{"denoms":[{"counts":[{"groupId":"BG000","value":"98"},{"groupId":"BG001","value":"86"},{"groupId":"BG002","value":"89"},{"groupId":"BG003","value":"273"}],"units":"Participants"}],"groups":[{"description":"Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance\n\nLenalidomide: In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.","id":"BG000","title":"Tandem Auto Transplant"},{"description":"Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance\n\nLenalidomide: In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.","id":"BG001","title":"RVD Consolidation"},{"description":"Initial autologous transplant followed by lenalidomide maintenance\n\nLenalidomide: In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.","id":"BG002","title":"Lenalidomide Maintenance"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"28","upperLimit":"70","value":"55"},{"groupId":"BG001","lowerLimit":"28","upperLimit":"69","value":"56"},{"groupId":"BG002","lowerLimit":"31","upperLimit":"66","value":"57"},{"groupId":"BG003","lowerLimit":"28","upperLimit":"70","value":"56"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"105"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"55"},{"groupId":"BG003","value":"168"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"18"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"77"},{"groupId":"BG002","value":"84"},{"groupId":"BG003","value":"242"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"13"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"11"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"48"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"68"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"68"},{"groupId":"BG003","value":"205"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"}]}],"title":"Multiracial"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"}]}],"title":"Unknown or Not Reported"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"63"},{"groupId":"BG003","value":"201"}],"title":"90-100"},{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"72"}],"title":"70-80"}]}],"description":"KPS describes patient-perceived global quality of life and functioning on a scale of 0-100.\n\n100: No evidence of disease; 90: Normal activity. Minor signs or symptoms of disease; 80: Normal activity with effort. Some signs or symptoms of disease; 70: Cares for self. Unable to continue normal activity; 60: Needs occasional assistance, but cares for most personal needs; 50: Needs considerable assistance and medical care; 40: Disabled. Needs special care and assistance; 30: Severely disabled. Hospital admission indicated; 20: Very sick. Active supportive therapy needed; 10: Moribund; 0: Dead","paramType":"COUNT_OF_PARTICIPANTS","title":"Karnofsky Performance Score (KPS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"72"},{"groupId":"BG003","value":"210"}],"title":"Standard"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"63"}],"title":"High"}]}],"description":"Participants on this study will be stratified for the purposes of statistical analysis into high-risk and standard risk-groups. High-risk multiple myeloma is defined by the presence of high beta-2 microglobulin (\\> 5.5mg/L) or the presence of cytogenetic abnormalities including t(4;14), t(14;20), t(14;16), deletion (17p) detected by FISH or standard cytogenetics, deletion 13 detected by standard cytogenetics only or aneuploidy. Participants without cytogenetic analysis available and beta-2 microglobulin ≤ 5.5mg/L or with deletion 13 detected by FISH will be classified as standard-risk disease.","paramType":"COUNT_OF_PARTICIPANTS","title":"Diseae Risk at BMT CTN 0702 Enrollment","unitOfMeasure":"Participants"}]}